[HTML] sciencedirect.com

[HTML][HTML] Overall survival update for patients with metastatic castration-resistant prostate cancer treated with capivasertib and docetaxel in the phase 2 ProCAID clinical …

SJ Crabb, G Griffiths, D Dunkley, N Downs, M Ellis… - European Urology, 2022 - Elsevier
Abstract The PI3K/AKT/PTEN pathway is frequently deregulated in metastatic castration-
resistant prostate cancer (mCRPC). ProCAID was a phase 2 trial assessing addition of the …
被引用次数：21 相关文章

Overall survival update for patients with metastatic castration-resistant prostate cancer treated with Capivasertib and docetaxel in the Phase 2 ProCAID clinical trial

SJ Crabb, G Griffiths, D Dunkley, N Downs… - European …, 2022 - eprints.soton.ac.uk
The PI3K/AKT/PTEN pathway is frequently deregulated in metastatic castration-resistant
prostate cancer (mCRPC). ProCAID was a phase 2 trial assessing addition of the AKT1/2/3 …

Overall survival update for patients with metastatic castration-resistant prostate cancer treated with capivasertib and docetaxel in the phase 2 ProCAID clinical trial

SJ Crabb, G Griffiths, D Dunkley, N Downs… - European …, 2022 - eprints.gla.ac.uk
The PI3K/AKT/PTEN pathway is frequently deregulated in metastatic castration-resistant
prostate cancer (mCRPC). ProCAID was a phase 2 trial assessing addition of the AKT1/2/3 …

Overall Survival Update for Patients with Metastatic Castration-resistant Prostate Cancer Treated with Capivasertib and Docetaxel in the Phase 2 ProCAID Clinical …

SJ Crabb, G Griffiths, D Dunkley, N Downs… - European …, 2022 - clok.uclan.ac.uk
The PI3K/AKT/PTEN pathway is frequently deregulated in metastatic castration-resistant
prostate cancer (mCRPC). ProCAID was a phase 2 trial assessing addition of the AKT1/2/3 …

Overall Survival Update for Patients with Metastatic Castration-resistant Prostate Cancer Treated with Capivasertib and Docetaxel in the Phase 2 ProCAID Clinical …

SJ Crabb, G Griffiths, D Dunkley, N Downs… - European …, 2022 - europepmc.org
The PI3K/AKT/PTEN pathway is frequently deregulated in metastatic castration-resistant
prostate cancer (mCRPC). ProCAID was a phase 2 trial assessing addition of the AKT1/2/3 …

Overall Survival Update for Patients with Metastatic Castration-resistant Prostate Cancer Treated with Capivasertib and Docetaxel in the Phase 2 ProCAID Clinical …

SJ Crabb, G Griffiths, D Dunkley… - European …, 2022 - pubmed.ncbi.nlm.nih.gov
The PI3K/AKT/PTEN pathway is frequently deregulated in metastatic castration-resistant
prostate cancer (mCRPC). ProCAID was a phase 2 trial assessing addition of the AKT1/2/3 …

Overall Survival Update for Patients with Metastatic Castration-resistant Prostate Cancer Treated with Capivasertib and Docetaxel in the Phase 2 ProCAID Clinical …

SJ Crabb, G Griffiths, D Dunkley, N Downs… - European …, 2022 - clok.uclan.ac.uk
The PI3K/AKT/PTEN pathway is frequently deregulated in metastatic castration-resistant
prostate cancer (mCRPC). ProCAID was a phase 2 trial assessing addition of the AKT1/2/3 …